

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/534,650	05/12/2005	Darren Mckerrecher	100897 - 1P US 6547 EXAMINER	
9629	7590 08/08/2006			
MORGAN LEWIS & BOCKIUS LLP			MORRIS, PATRICIA L	
	SYLVANIA AVENUE NY ΓΟΝ, DC 20004	V	ART UNIT	PAPER NUMBER
			1625	
			DATE MAILED: 08/08/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/534,650	MCKERRECHER ET AL.				
Office Action Summary	Examiner	Art Unit				
	Patricia L. Morris	1625				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w. - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirr viil apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on						
<u> </u>	This action is FINAL . 2b) This action is non-final.					
·=	,—					
•	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 1-10 is/are pending in the application.	Claim(s) <u>1-10</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdray	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.	· · · 					
7) Claim(s) is/are objected to.						
8) Claim(s) 1-10 are subject to restriction and/or e	election requirement.					
Application Papers		·				
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119	•					
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:						
	2. Certified copies of the priority documents have been received in Application No					
•	3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau	, , , ,					
* See the attached detailed Office action for a list of the certified copies not received.						
•						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal Pi 6) Other:	ite atent Application (PTO-152)				
0)						

Art Unit: 1625

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, the instance wherein A is a pyridine and R³,R⁵ and R⁶ represent nonheterocyclic groups.

Group II, the instance wherein A is a pyridine, R³ is an isoxazole and R⁵, R⁶ represent nonheterocyclic groups.

Group III, the instances wherein X is a pyridine, R³ is a thiophene and R⁵, R⁶ represent nonheterocyclic groups.

Group IV, the instance wherein A is a thiazole and R³, R⁵ and R⁶ represent non-heterocyclic groups.

Group V, any compound not set forth in Groups I-IV because claim 1 is too vague to further group.

Group VI, claim 8, drawn to multiple uses.

Group VII, claim 9, drawn to multiple processes.

Group X, claim 10, drawn to an intermediate.

Art Unit: 1625

The inventions listed as Groups I-X do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I-V and VII are related as products and processes of preparing. In the instant case, the products as claimed can be made by materially different processes as evidenced by applicants'own claims and specification.

Groups I-V and X are related as final products and as intermediates. In the instant case, the intermediates have other uses such as sedatives, corrosion inhibitors, antifogging agents, etc.

Due to the numerous variables R³, R⁵, R⁶, etc., and their widely divergent meanings, and the numerous processes of preparing, a precise listing of inventive groups cannot be made.

Illustrative of different inventive concepts may be made by reference to the compounds in the Examples of the instant application, as for example:

the compounds of

- I. Example 2.
- II. Example 3
- III. Example 6 etc,

The claims herein lack unity of invention under PCT Rule 13.1 and 13.2 since the compounds defined in the claims lack a significant structural element qualifying as the special technical feature that defines a contribution over the prior art. The compounds claimed contain a benzofuran group, which does not define a contribution over the prior art. The substituents on the structure vary extensively and when taken as a whole result in vastly different compounds. The claims encompass all heterocyclic chemistry. Accordingly, unity of invention is considered

Art Unit: 1625

to be lacking and restriction of the invention in accordance with the rules of unity of invention is considered to be proper.

In the event of any election of either Groups V or VIII, applicants are required to elect a single compound.

Claims 1-7 will be examined to the extent readable on the elected compounds.

37 CFR 1.475(b) an international or a national stage application containing claims drawn to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combination of categories:

- (1) A product and a process specifically adapted for the manufacture of said product; or
- (2) A product and process of use of said product; or
- (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- (4) A process and an apparatus or means specifically designed for carrying out the said process; or
- (5) A product, a process specifically adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.
- (c) If an application contains claims to more or less than one of the combination of categories of inventions set forth in paragraph (b) of this section, unity of invention might not be present.

Art Unit: 1625

(d) If multiple products, processes of manufacture, or uses are claimed, the first invention of the category first mentioned in the claims of the application and the first recited invention of each of the other categories relied thereto will be considered as the main invention in the claims.

(e) The determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claim or as alternatives within a single claim.

Once applicant has elected a compound from Groups I, II, III, IV or V, he is permitted to have, in view of the fact that this application enters the national stage through 35 U.S.C. 371, no more than one process of preparing that elected product and one method of use. See PCT Rule 13.2.

Also, note 1134 OG 197, where it is specifically recited that under PCT Rule 13.2(i), claims are permitted to <u>one</u> product and <u>one</u> process of preparing.

In the event of an election of either Groups I - V, applicants, applicants are requested to elect one single process of preparing and one method of use, *i.e.*, a specific disease.

Because these inventions lack unity of invention for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter restriction for examination purposes as indicated is proper

Applicant may file the divisional subject matter noted in divisional applications. If applicant wishes a generic expression of the elected invention the claims here need be amended to reflect that election.

This restriction requirement is being written as previous experience has indicated that with Foreign applicants and the inherent time delays, applicants' representative is better able to make

Art Unit: 1625

an informed, correct, election of the invention applicants would wish to have prosecuted here if applicants are given the opportunity to see the restriction requirement laid out, and given the time to make an informed decision.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia L. Morris whose telephone number is (571) 272-0688. The examiner can normally be reached on Mondays through Fridays.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

Art Unit: 1625

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Patricia L. Morris Primary Examiner Art Unit 1625

plm August 3, 2006